Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis

In the phase III RADIANT‐4 study, everolimus improved median progression‐free survival (PFS) by 7.1 months in patients with advanced, progressive, well‐differentiated (grade 1 or grade 2), non‐functional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio, 0.48; 95% confid...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Sci
Huvudupphovsmän: Fazio, Nicola, Buzzoni, Roberto, Delle Fave, Gianfranco, Tesselaar, Margot E., Wolin, Edward, Van Cutsem, Eric, Tomassetti, Paola, Strosberg, Jonathan, Voi, Maurizio, Bubuteishvili‐Pacaud, Lida, Ridolfi, Antonia, Herbst, Fabian, Tomasek, Jiri, Singh, Simron, Pavel, Marianne, Kulke, Matthew H., Valle, Juan W., Yao, James C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2017
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765303/
https://ncbi.nlm.nih.gov/pubmed/29055056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13427
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk